申请人:ILEX Oncology, Inc.
公开号:US20020045663A1
公开(公告)日:2002-04-18
The present invention concerns a method for preventing and/or treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine (D-DFMO) or an analog of D-DFMO to the patient. D-DFMO or an analog thereof is administered at a dose of about 0.05 to about 20.0 gm/M
2
/day. D-DFMO or an analog thereof may be administered more than once for the treatment and/or prevention of cancer. Methods of administration as well as compositions and formulations of substantially purified D-DFMO and analogs of D-DFMO are described.
本发明涉及一种预防和/或治疗患者癌症的方法,包括向患者施用有效量的基本纯化的二氟甲基鸟氨酸D对映体(D-DFMO)或D-DFMO类似物。D-DFMO或其类似物的给药剂量约为0.05至约20.0 gm/M
2
/天。D-DFMO或其类似物可多次给药,用于治疗和/或预防癌症。本文描述了基本纯化的 D-DFMO 和 D-DFMO 类似物的给药方法以及组合物和制剂。